Guides
Canfora
No. Belbuca and Suboxone both contain buprenorphine, but they are different products for different conditions. Belbuca is a buccal film with a low dose of buprenorphine alone, approved in the US for chronic pain. Suboxone is a sublingual film combining a much higher dose of buprenorphine with naloxone, approved for opioid use disorder. Sublocade and Brixadi are long-acting buprenorphine injections, also for opioid use disorder. They aren’t interchangeable, and they shouldn’t be taken together.

The short answer
| Belbuca | Suboxone | Sublocade | Brixadi | |
|---|---|---|---|---|
| Ingredients | Buprenorphine | Buprenorphine + naloxone (4:1) | Buprenorphine extended-release | Buprenorphine extended-release |
| Form | Film stuck to the inside of the cheek | Film under the tongue (generic tablets also exist) | Subcutaneous injection | Subcutaneous injection |
| US approval | Chronic pain needing daily long-term opioid | Opioid use disorder | Moderate to severe opioid use disorder | Moderate to severe opioid use disorder |
| Strengths | 75 to 900 micrograms | 2/0.5 to 12/3 mg | 100 mg and 300 mg | Weekly and monthly formulations |
| How often | Every 12 hours | Once daily | Monthly (at least 26 days apart) | Weekly or monthly |
| Who gives it | Patient | Patient | Clinician only, REMS-certified setting | Clinician only, REMS-certified setting |
The scale is the key difference: the maximum Belbuca dose (900 micrograms twice a day) is about 1.8 mg of buprenorphine a day, while common Suboxone maintenance doses are 8–16 mg a day or more. US information, Stand: November 2026; brands and approvals differ elsewhere (in the UK and Australia, buprenorphine for opioid dependence is given as sublingual tablets, Espranor wafers or Buvidal injections, and buprenorphine for pain mainly as patches).
Naloxone is an opioid blocker that is poorly absorbed under the tongue. Taken as directed, it does almost nothing. If someone dissolves and injects Suboxone, the naloxone becomes active and can trigger withdrawal, which discourages misuse. Belbuca is a pain medicine with a much lower buprenorphine dose, so it doesn’t include naloxone.
Since the Consolidated Appropriations Act of 2023 removed the “X-waiver”, any practitioner with a current DEA registration that includes Schedule III can prescribe buprenorphine for opioid use disorder. Sublocade and Brixadi are dispensed only to certified healthcare settings under their REMS programs. More practical notes are in our clinical pharmacy guide.
Call 911 if someone taking buprenorphine is very hard to wake, breathing slowly or has blue lips, and give naloxone if available. For questions about switching products, talk to the prescriber; don’t change on your own.
No. Belbuca contains much less buprenorphine per dose (micrograms vs milligrams).
Both treat opioid use disorder with buprenorphine, but Sublocade is a monthly injection without naloxone, given by a clinician; Suboxone is a daily film you take yourself.
No. They contain the same drug, and combining them adds risk without benefit.
Tests that look for buprenorphine detect both. Only Suboxone contains naloxone, which some labs also test for.
More on this topic: more practical prescribing and administration notes are collected in Clinical Pharmacy Notes: Practical Reference for Nurses and Pharmacists.
Medical disclaimer: this article is general information, not a diagnosis or a personal recommendation. Check with your doctor or pharmacist before starting, stopping or combining medicines. Read the full disclaimer.